CCR4 and T-cell non-Hodgkin lymphoma: In addition to these, a notable range of CCR4 antagonists has been evaluated in clinical studies, although mogamulizumab remains the sole approved CCR4 antagonist in oncology, specifically indicated for the treatment of T cell lymphomas.